Revolutionizing Cancer Care With Genomic Testing
In an interview with Targeted Oncology, David L. Bartlett, MD, discussed the utilization and growing importance of genomic testing in cancer care.
In an interview with Targeted Oncology, David L. Bartlett, MD, discussed the utilization and growing importance of genomic testing in cancer care.
TAR-210 was safe and showed promising clinical activity in patients with FGFR-altered high- and intermediate-risk non–muscle-invasive bladder cancer.
Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.
Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Combination nivolumab and nab-paclitaxel may be a safe and effective treatment for patients with muscle-invasive bladder cancer.
More people in their 40s, 30s and even 20s are diagnosed with colorectal cancer each year, and those diagnoses tend to have more advanced stages…
Monday, May 6th, 2024 10:00AM – 2:00PM ET The Ritz Carlton 1150 22nd St NW Washington, DC 20037 Register Today Friends of Cancer Research (Friends)…
The addition of PSMA-PET imaging to multi-parametric MRI was associated with an improvement in the detection of clinically significant prostate cancer.
Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study…